Pharmaceuticals, Biotechnology and Life Sciences
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will be focused on developing new therapies for autoimmune diseases that...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
The need for more effective protection against influenza continues to grow, as the virus consistently causes significant illness and mortality…
Study highlights GLP-1 companion effects, underscoring capability of Brightseed’s AI platform to identify and launch clinically-validated, natural health innovations SOUTH…
PARK CITY, Utah & IRVINE, Calif.–(BUSINESS WIRE)–BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced…
HOUSTON–(BUSINESS WIRE)–InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced receipt of a CE Certificate (No. 28620235524…
— CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and…
– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026…
First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT) TRX103 demonstrated exceptional…
BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron…
BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced…
Trial Evaluates Safety, Right Heart Functional Improvement, and Clinical Outcomes of Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) MENLO…
